Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy?

Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94

Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS (2009) 4.07

Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med (2008) 2.63

Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med (2009) 2.20

Diagnostic and prognostic value of serum C-reactive protein for screening for HIV-associated tuberculosis. Int J Tuberc Lung Dis (2013) 1.69

The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb) (2007) 1.49

Response to 'Does immune reconstitution promote active tuberculosis in patients receiving highly active antiretroviral therapy?' AIDS, 22 July 2005. AIDS (2005) 1.45

Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol (2010) 1.25

Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting? J Acquir Immune Defic Syndr (2011) 1.19

Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. BMC Infect Dis (2008) 1.14

Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART. Clin Dev Immunol (2010) 1.09

Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda. Afr Health Sci (2008) 0.93

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects. PLoS One (2013) 0.88

Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database. HIV Med (2013) 0.86

HIV-Associated Tuberculosis. Clin Dev Immunol (2010) 0.81

Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment. J Acquir Immune Defic Syndr (2016) 0.80

Integrated therapy for HIV and tuberculosis. AIDS Res Ther (2016) 0.80

'Tuberculosis' after commencing antiretroviral therapy in HIV patients from countries where Mycobacterium tuberculosis infection is common. AIDS (2006) 0.77

Challenges of Childhood TB/HIV Management in Malawi. Malawi Med J (2007) 0.77

Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques (2004) 6.42

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med (2005) 4.83

Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis (2004) 3.40

Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (2012) 3.09

Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS (2004) 2.76

Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med (2008) 2.63

Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet (2004) 2.54

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet (2011) 2.52

Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS (2005) 2.38

Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28

Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J (2006) 2.16

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet (2006) 2.14

The distribution of mitochondrial activity in relation to optic nerve structure. Arch Ophthalmol (2002) 2.06

Newly diagnosed HIV infections: review in UK and Ireland. BMJ (2005) 2.00

Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ (2005) 1.93

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS (2002) 1.74

Lung remodeling in pulmonary tuberculosis. J Infect Dis (2005) 1.71

Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS (2006) 1.71

Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis (2004) 1.70

Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med (2006) 1.69

Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr Opin Pulm Med (2005) 1.60

Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS (2010) 1.57

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr (2012) 1.53

Purified protein derivative-activated type 1 cytokine-producing CD4+ T lymphocytes in the lung: a characteristic feature of active pulmonary and nonpulmonary tuberculosis. J Infect Dis (2002) 1.51

Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens. Int J Tuberc Lung Dis (2011) 1.46

Biomarkers of treatment response in clinical trials of novel antituberculosis agents. Lancet Infect Dis (2007) 1.32

Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. J Acquir Immune Defic Syndr (2011) 1.31

Splicing of the mycobacteriophage Bethlehem DnaB intein: identification of a new mechanistic class of inteins that contain an obligate block F nucleophile. J Biol Chem (2009) 1.31

Novel beta-barrel fold in the nuclear magnetic resonance structure of the replicase nonstructural protein 1 from the severe acute respiratory syndrome coronavirus. J Virol (2007) 1.30

Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3. J Virol (2008) 1.27

Molecular recognition of oligosaccharide epitopes by a monoclonal Fab specific for Shigella flexneri Y lipopolysaccharide: X-ray structures and thermodynamics. Biochemistry (2002) 1.23

Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 1.23

Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J Acquir Immune Defic Syndr (2002) 1.22

Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 1.20

A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses (2007) 1.18

Long-term trends in adherence to antiretroviral therapy from start of HAART. AIDS (2010) 1.17

Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother (2007) 1.16

HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J (2008) 1.13

Rapid diagnosis of smear-negative tuberculosis using immunology and microbiology with induced sputum in HIV-infected and uninfected individuals. PLoS One (2007) 1.10

In vivo and in vitro studies of a novel cytokine, interleukin 4delta2, in pulmonary tuberculosis. Am J Respir Crit Care Med (2005) 1.10

The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS (2003) 1.09

Systemic amyloidosis in England: an epidemiological study. Br J Haematol (2013) 1.08

Nuclear magnetic resonance structure of the N-terminal domain of nonstructural protein 3 from the severe acute respiratory syndrome coronavirus. J Virol (2007) 1.07

Tuberculosis and HIV co-infection: a practical therapeutic approach. Drugs (2006) 1.07

Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med (2007) 1.06

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. J Antimicrob Chemother (2011) 1.06

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS (2002) 1.05

Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis (2002) 1.05

Structural genomics of the severe acute respiratory syndrome coronavirus: nuclear magnetic resonance structure of the protein nsP7. J Virol (2005) 1.04

Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? AIDS (2002) 1.02

Stability of antiretroviral regimens in patients with viral suppression. AIDS (2008) 1.00

A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study. PLoS Clin Trials (2006) 0.95

Ongoing changes in HIV RNA levels during untreated HIV infection: implications for CD4 cell count depletion. AIDS (2010) 0.94

The stability of mRNA encoding IL-4 is increased in pulmonary tuberculosis, while stability of mRNA encoding the antagonistic splice variant, IL-4delta2, is not. Tuberculosis (Edinb) (2006) 0.94

Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy. AIDS (2002) 0.93

Structure-activity studies with pheromone-binding proteins of the gypsy moth, Lymantria dispar. Chem Senses (2003) 0.93

Highly active antiretroviral therapy and cervical intraepithelial neoplasia. AIDS (2002) 0.91

Expression of a novel cytokine, IL-4delta2, in HIV and HIV-tuberculosis co-infection. AIDS (2005) 0.90

Long-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathy. HIV Clin Trials (2006) 0.90

Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis. Proc Biol Sci (2006) 0.90

Increased proportions of activated and proliferating memory CD8+ T lymphocytes in both blood and lung are associated with blood HIV viral load. J Acquir Immune Defic Syndr (2003) 0.90

Nuclear magnetic resonance structure of the nucleic acid-binding domain of severe acute respiratory syndrome coronavirus nonstructural protein 3. J Virol (2009) 0.89

The length of cytochrome c oxidase-negative segments in muscle fibres in patients with mtDNA myopathy. Neuromuscul Disord (2002) 0.89

Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals. J Acquir Immune Defic Syndr (2004) 0.88

Nuclear magnetic resonance structure shows that the severe acute respiratory syndrome coronavirus-unique domain contains a macrodomain fold. J Virol (2008) 0.88

HIV as a chronic disease. Clin Med (2009) 0.87

Detection of mycobacterial antigen responses in lung but not blood in HIV-tuberculosis co-infected subjects. AIDS (2006) 0.86

Interferon gamma assays for tuberculosis. Lancet Infect Dis (2005) 0.84

Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients: the role of gender. J Acquir Immune Defic Syndr (2007) 0.84

Unlocking the potential: longitudinal audit finds multifaceted education for general practice increases HIV testing and diagnosis. Sex Transm Infect (2012) 0.84

A novel point mutation in the mitochondrial tRNA(Trp) gene produces a neurogastrointestinal syndrome. Eur J Hum Genet (2004) 0.84

The relationship between CD4 cell count nadirs and the toxicity profiles of antiretroviral regimens. Antivir Ther (2005) 0.83

An important diagnosis to consider in recurrent meningitis. JRSM Short Rep (2013) 0.82

Citrobacter koseri meningitis: another freediving risk? J Infect (2010) 0.82

Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. AIDS (2014) 0.82

First confirmed case of Crimean-Congo haemorrhagic fever in the UK. Lancet (2013) 0.81

Electrospray ionization-induced protein unfolding. J Am Soc Mass Spectrom (2012) 0.80

The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. J Infect Dis (2005) 0.80

NMR assignment of the domain 513-651 from the SARS-CoV nonstructural protein nsp3. Biomol NMR Assign (2007) 0.80

Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies/ml followed for up to 4 years. AIDS (2003) 0.79

Synthesis and immunochemical characterization of protein conjugates of carbohydrate and carbohydrate-mimetic peptides as experimental vaccines. Bioorg Med Chem (2004) 0.79

Determination of bronchoalveolar lavage leukocyte populations by flow cytometry in patients investigated for respiratory disease. Cytometry (2002) 0.78

The utility of different bioinformatics algorithms for genotypic HIV-1 tropism testing in a large clinical cohort with multiple subtypes. AIDS (2014) 0.78

The pathogen recognition sensor, NOD2, is variably expressed in patients with pulmonary tuberculosis. BMC Infect Dis (2007) 0.78

NMR assignment of the nonstructural protein nsp3(1066-1181) from SARS-CoV. Biomol NMR Assign (2008) 0.78

Socioeconomic status and response to antiretroviral therapy in high-income countries: a literature review. AIDS (2016) 0.78